CD274 and non-small cell lung carcinoma: In NSCLC patients treated with anti-PD or anti-PD-L1 antibodies, bTMB ≥ 6 was associated with higher response rates (39.3% vs. 9.1%, p = 0.02) and superior PFS (HR 0.39, p = 0.01) [106].